CEBPA Mutation Analysis

Clinical Significance

The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly those with chromosome analyses showing normal diploid karyotype, Cytogenetically Normal (CN). CN-AML that have CEBPA mutations show favorable outcome compared to other groups of CN-AML.
Testing for CEBPA mutation, along with NPM1 (test code 16158-NPM (Exon 12) Mutation Analysis, Cell-based) is recommended for all patients with CN-AML.

Specimen Requirements

5.0 mL Whole Blood in a Lavender Top Tube(s) - EDTA

Transport And Storage

7 days Ambient
7 days Refrigerated

Collection Instructions

 

Minimum Volume

2.0 mL

Neonatal Volume

Reference Range:

Not detected

Methodology:

• Polymerase Chain Reaction (PCR)

Clinical Significance

The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly those with chromosome analyses showing normal diploid karyotype, Cytogenetically Normal (CN). CN-AML that have CEBPA mutations show favorable outcome compared to other groups of CN-AML.
Testing for CEBPA mutation, along with NPM1 (test code 16158-NPM (Exon 12) Mutation Analysis, Cell-based) is recommended for all patients with CN-AML.

CDM

00919218

CPT Coding

81218